Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons
doi: 10.4049/jimmunol.160.12.5729 189 MazzoniABronteVVisintinASpitzerJHApolloniESerafiniPet al
However, complete UBASH3A deficiency accelerates T1D onset in NOD mice and rats (80, 81)
Additional information Digital Features To view digital features for this article go to Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
US$ 29.76
US$ 27.55
US$ 23.08
US$ 24.43
